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Background: Genomic prediction aims to leverage genome-wide genetic data towards better disease diagnostics
and risk scores. We have previously published a genomic risk score (GRS) for celiac disease (CD), a common and
highly heritable autoimmune disease, which differentiates between CD cases and population-based controls at a
clinically-relevant predictive level, improving upon other gene-based approaches. HLA risk haplotypes, particularly
HLA-DQ2.5, are necessary but not sufficient for CD, with at least one HLA risk haplotype present in up to half of
most Caucasian populations. Here, we assess a genomic prediction strategy that specifically targets this common
genetic susceptibility subtype, utilizing a supervised learning procedure for CD that leverages known HLA-DQ2.5 risk.
Methods: Using L1/L2-regularized support-vector machines trained on large European case-control datasets, we
constructed novel CD GRSs specific to individuals with HLA-DQ2.5 risk haplotypes (GRS-DQ2.5) and compared them
with the predictive power of the existing CD GRS (GRS14) as well as two haplotype-based approaches, externally
validating the results in a North American case-control study.
Results: Consistent with previous observations, both the existing GRS14 and the GRS-DQ2.5 had better predictive
performance than the HLA haplotype approaches. GRS-DQ2.5 models, based on directly genotyped or imputed
markers, achieved similar levels of predictive performance (AUC = 0.718-0.73), which were substantially higher than
those obtained from the DQ2.5 zygosity alone (AUC = 0.558), the HLA risk haplotype method (AUC = 0.634), or the
generic GRS14 (AUC = 0.679). In a screening model of at-risk individuals, the GRS-DQ2.5 lowered the number of
unnecessary follow-up tests for CD across most sensitivity levels. Relative to a baseline implicating all DQ2.5-positive
individuals for follow-up, the GRS-DQ2.5 resulted in a net saving of 2.2 unnecessary follow-up tests for each justified
test while still capturing 90 % of DQ2.5-positive CD cases.
Conclusions: Genomic risk scores for CD that target genetically at-risk sub-groups improve predictive performance
beyond traditional approaches and may represent a useful strategy for prioritizing individuals at increased risk of
disease, thus potentially reducing unnecessary follow-up diagnostic tests.Background
Genome-wide association studies (GWAS) have identified
large numbers of genetic loci associated with complex
human disease, particularly for many autoimmune diseases,
where disease susceptibility is typically strongly linked to the
human leukocyte antigen (HLA) region as well as loci out-
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genomic-based prediction models to be developed with
substantial predictive power [7–12]. As new light continues
to be shed on the fundamental role of these genetic links
in disease pathogenesis, it is becoming increasingly likely
that genomic-based tools to predict disease development
and risk, as well as prognosis and clinical course, may be
harnessed and applied with direct relevance to patient care.
Despite these advances, suitable clinical tools that
quantify genomic risk for complex disease remain largely
unrealized. This is largely due to a lack of understanding
regarding how such tools might be utilized in clinical
settings, hampered by the complexity of integrating such
data into a risk model that often incorporates manycle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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tory investigations. The role of genomic risk prediction
in existing risk models and diagnostic pathways is still
being determined, including whether genomic prediction
is optimal as a complement or a replacement for existing
assays. For autoimmune diseases in particular, genomic
prediction needs to demonstrate improved risk stratifica-
tion beyond known HLA risk haplotypes and have suffi-
cient predictive power, particularly given the low disease
prevalence in the general population (typically 1 % or
less). Here, we have sought to identify specific scenarios
where there is a major clinical need to improve risk pre-
diction in a highly heritable autoimmune disease, celiac
disease (CD). We first show that genomic risk prediction
methods have clear advantages over existing approaches
for CD risk prediction, and next assess the clinical implica-
tions of genomic risk prediction for disease management.
Celiac disease (CD) is a common systemic auto-
immune disease caused by dietary gluten in genetically
susceptible individuals [13–15]. CD affects approxi-
mately 1 % of the Western world and is strongly her-
itable (approximately 80 % on the liability scale) [16].
The major genetic association is in the MHC locus,
with specific HLA haplotypes present in almost all
(approximately 99.6 %) cases: HLA-DQ2.5 (DQA1*05/
DQB1*02) in approximately 88 %, HLA-DQ2.2 (DQA1*02/
DQB1*02) in approximately 4 %, and/or HLA-DQ8
(DQA1*03/DQB1*03:02) in approximately 6 % [17]. This
HLA association underpins the crucial pathogenic role of
CD4+ T cells targeting a restricted repertoire of immuno-
genic gluten peptides [18]. Recent GWAS in CD implicate
at least 41 other non-HLA loci with more modest contri-
butions to risk [3, 4, 6, 19–22]. These regions are all linked
to aspects of immune system function, and are likely to im-
pact on CD susceptibility or clinical behavior.
Current diagnosis of CD relies on the presence of CD-
specific autoantibodies and a confirmatory small-bowel
biopsy to demonstrate the characteristic intestinal villous
atrophy [13]. Importantly, while both methods are useful
for detecting current CD, they do not provide predictive
information on the future risk of developing CD in a
person without active disease. Early detection of CD is a
clinical priority in order to reduce long-term risk of dis-
ease complications, especially for individuals at higher
risk of CD, such as those who are a first-degree family
members of an affected individual or those who have a
related autoimmune disease. However, the follow-up
care of people without active CD, particularly the ques-
tion of whether and how often to perform follow-up
testing, remains unresolved. This challenge stems from
the desire for early disease detection conflicting with the
need for minimizing repeated testing that is inconveni-
ent, costly, anxiety-inducing, and entirely unnecessary
for those individuals who will never develop disease.Since the development of CD depends so strongly on
several HLA risk haplotypes, HLA typing is able to
achieve close to 100 % sensitivity in detecting at-risk in-
dividuals while also excluding those at very low risk. As
a result, HLA typing for CD has been widely embraced
in clinical practice [23]. Indeed, recent consensus guide-
lines recommend HLA typing as a first-line investigation
in asymptomatic children at risk of CD (for instance, if
they have a family history of CD) [13]. Further, combin-
ing HLA typing with CD-serology may also provide a
more cost-effective diagnostic approach in some situa-
tions such as population screening by identifying false-
positive serology in non-genetically susceptible individuals,
thus reducing the number of unnecessary and expensive
confirmatory small bowel biopsies [24].
The presence of at least one of the CD-related HLA
haplotypes, while necessary for the development of dis-
ease, carries little predictive value for eventual CD devel-
opment and therefore has no role as a sole diagnostic
for CD. The CD-related genotypes are highly prevalent
in the community, with 30-40 % of Europeans and up to
56 % Australians carrying at least one [24]. Despite the
fact that different HLA haplotypes impart varying levels
of risk for CD, specifically HLA-DQ2.5 > DQ8 > DQ2.2,
these differences in relative risk have not translated
meaningfully into clinical practice. Thus HLA typing re-
sults are typically interpreted as simply ‘susceptibility
present’ or ‘susceptibility absent’ regardless of the par-
ticular HLA haplotype detected, and therefore used pri-
marily to exclude CD but not to detect high-risk
individuals nor to predict future risk of disease [13].
Notwithstanding the limited clinical role of HLA typ-
ing, there has been renewed interest in the role of spe-
cific HLA alleles in the development on CD, with the
risk of CD being far higher in children who are HLA-
DQ2.5 homozygous (or have two copies of DQB1*02)
than among those who are HLA-DQ2.5 heterozygous or
are positive for HLA-DQ8 [25, 26]. A gene-dose effect
has been reported, with HLA-DQ2.5 homozygosity asso-
ciated in some studies with a more severe clinical pres-
entation of CD, refractory disease, and a slower rate of
intestinal healing on treatment [27, 28]. As a result,
HLA-DQ2.5 zygosity status is a major variable in a
recently proposed CD prognostic modeling tool [29].
Collectively, these studies highlight the important role of
the HLA risk haplotypes, especially HLA-DQ2.5, in CD
development, prognosis, and clinical behavior, but also
highlight the current limitations in the clinical utility of
HLA typing. There is a major need to develop tools that
are more informative than HLA typing particular for
those who have already been shown to possess at least
one HLA-DQ2.5 allele (DQ2.5+).
We have recently performed a proof-of-principle study
demonstrating that genomic data, derived from multiple
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upon current genetic testing based on HLA typing [7]. A
CD genomic risk score (GRS) based on genome-wide
single nucleotide polymorphisms (SNPs), denoted here
the ‘GRS14’ [8], was induced by supervised learning
models trained on a British case-control GWAS study
[30, 31]. We have established the robustness of GRS14
to discriminate CD patients from population-based con-
trols in UK, Dutch, Finnish, and Italian studies [3, 4, 32],
achieving predictive performance (area under the
receiver-operating characteristic curve (AUC)) sub-
stantially higher than other methods which attribute
risk based on 57 non-HLA SNPs together with HLA
alleles [33].
A recent large-scale CD Immunochip GWAS [34] has
shown that statistical imputation of non-SNP genetic
variants via SNP2HLA [35], including HLA alleles and
amino-acid polymorphisms in HLA genes, enabled fine-
mapping of CD-associated variation to a greater
resolution than that afforded by SNPs alone, and
subsequently substantially increased the explained
heritability of CD. However, the implications for CD
risk prediction had not been assessed.
Here, we first externally validate the predictive power
of the existing GRS14 and novel variants thereof in a
North American CD case-control study [22, 36], com-
paring their performance to a previous HLA haplotype
risk approach. Next, we focus on the DQ2.5+ subset of
individuals, and develop HLA-DQ2.5-specific genomic
risk scores, one based on SNPs and others based on
SNPs together with SNP2HLA-imputed markers [35].
Finally, we assess the HLA-DQ2.5-specific genomic risk
scores in screening scenarios to determine the number
of unnecessary follow-up tests saved relative to other
approaches.
Methods
Genotype and phenotype data
We obtained the North American dataset (cases and
controls) from NCBI dbGaP (accession phs000274.v1.p1).
Samples were genotyped on the Illumina 660W Quad v1A
platform, assaying 2,246 individuals in total (1,716 cases,
530 controls, 723 male, 1,523 female). Individuals were
considered to have confirmed CD based on either:
(1) characteristic findings on small bowel biopsy ac-
cording to ESPGHAN criteria; (2) biopsy-proven
dermatitis herpetiformis; or (3) positive celiac serology
panel (transglutaminase (tTG) and endomysial (EMA)
antibodies). Controls were originally from the Illumina
iControl database, matched by the original study au-
thors for age, sex, and ethnicity [36]. To minimize the
possibility of artificially inflating the apparent predict-
ive ability of the models [37], we performed several
stages of quality control on the genotype data using plink1.9 [38–40]: removing non-autosomal SNPs, filtering SNPs
by minor allele frequency (MAF) <1 %, missingness >10 %,
deviation from Hardy-Weinberg equilibrium in controls
P <5 × 10−6, and filtering of individuals with missing-
ness >10 %. Next we removed 2,473 SNPs with case/
control SNP differential missingness P <10−3. We itera-
tively used principal component analysis (PCA), imple-
mented in flashpca 1.2 [41], to identify outlier
individuals, defined here as individuals with PC coordi-
nates more than 3 standard deviations from the median
of each of PC 1-50. After removing those individuals,
PCA was repeated to verify the results. We used two it-
erations of this procedure, resulting in 1,697 individuals
remaining. Finally, we removed one of two individuals
with identity-by-descent π^ < 0:05 (one individual was
removed). The final QCd dataset consisted of 1,696 in-
dividuals (1,259 cases, 437 controls, 546 male, and
1,150 female) over 518,770 autosomal SNPs. The avail-
able clinical characteristics of the post-QC data are
shown in Table 1.
The genotype data for the UK (n = 6,785), Finnish
(n = 2,476), Dutch (n = 1,649), and Italian (n = 1,040)
cohorts have been previously described [3, 4, 8, 32];
these datasets were genotyped on the Illumina 670-
QuadCustom-v1, 610-Quad, and 1.2M-DuoCustom-v1
genome-wide SNP arrays. Each cohort underwent add-
itional separate QC: removing SNPs with MAF <1 %,
Hardy-Weinberg deviation from equilibrium in controls
P <5 × 10−6, missingness >10 %, or differential case/control
missingness P <10−3, and removing samples with missing-
ness >10 % or IBD π^ < 0:1, before being combined into a
single dataset consisting of n = 11,912 samples and 500,821
SNPs. The Immunochip dataset (n = 16,002) was assayed
on a custom Illumina fine-mapping array (Immunochip)
comprising 115,746 SNPs after QC, as described [3, 8]
(with SNPs further filtered by MAF >0.5 %), of which
17,848 were common to both the Immunochip and GWA
arrays. Since some individuals were genotyped both in the
UK GWA dataset and in the Immunochip dataset, when
combining the GWA and Immunochip datasets we in-
cluded only individuals with pairwise identity-by-descent
(plink IBD) π^ < 0:1, resulting in n = 19,715 individuals
in total.
In order to check whether the putative European descent
of the North American individuals was indeed the case, we
also combined an LD-thinned (plink –indep-pairwise) ver-
sion of the North American data with an LD-thinned ver-
sion of the UK, Finnish, Dutch, and Italian GWA data and
performed PCA on the combined data (Additional file 1:
Figure S1). Finally, we computed the fixation index Fst [42]
(plink –fst) on a combined dataset (European +North
American) consisting of the 224 of the 228 SNPs in the
GRS14, with the European and North American samples
as two clusters.
Table 1 The North American NIDDK-CIDR dataset clinical characteristics (post QC)
Controls Cases
Total cases Biopsy and Serology Biopsy only Serology only Unknown method Diagnosis age, years (median, range)
Male 192 354 163 130 36 25 49 (2-90)
Female 245 905 463 295 62 85 44 (0-84)
Total 437 1,259 626 425 98 110
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protocols were approved by the relevant institutional or
national ethics committees. Details for the ethics proto-
cols for the European GWA and Immunochip datasets
are given in [3, 4]. The North American NIDDK-
CIDR dataset was obtained from the NCBI Database
of Genotypes and Phenotypes (dbGaP), accession
phs000274.v1.p1, following their respective access
protocols.
Imputation of HLA alleles and other markers
While SNP arrays only produce unphased alleles, statis-
tical methods can exploit patterns of linkage disequilib-
rium to impute haplotypes (phased alleles) and other
forms of genetic variation, based on a reference panel
where both the SNPs and the imputed variation are
known (a training dataset). This procedure is conceptu-
ally the same as used when imputing, for example,
millions of 1000 Genome genotypes based on a smaller
set of hundreds of thousands of assayed genotypes.
As the majority of CD-related variation is found within
the HLA, we imputed HLA variation, employing two
complementary methods. First, we imputed HLA-DQA1
and HLA-DQB1 alleles from the SNPs using the R pack-
age HIBAG 1.2.3 [43], using the European hg18 HLA4
reference dataset. Based on the imputed HLA alleles, we
inferred each individual’s heterodimer type as one of
DQ2.5 heterozygous, DQ2.5 homozygous, DQ2.2, or
DQ8, according to the mapping in [8]. Following [33],
the HLA risk score was assigned as low for individuals that
did not have any of the CD risk heterodimers (DQ2.2,
DQ8, DQ2.5-heterozygous, and DQ2.5-homozygous). High
risk was assigned to individuals with DQ2.5-homozygous
or those with both DQ2.5-heterozygous and DQ2.2.
Medium risk was assigned to all other remaining individ-
uals. The HLA risk profiles were coded as 0 for low, 1 for
medium, and 2 for high risk. We did not examine the 57
non-HLA SNPs used in [33] as these are only present on
Immunochip arrays and not on the genome-wide arrays,
and were not well tagged by the existing SNPs on the
genome-wide arrays.
Another imputation approach, SNP2HLA [35], has
proven to be particularly useful for fine-mapping of
the HLA region with regards to association with sev-
eral autoimmune diseases, including CD [34], and forexplaining more of the heritability of disease. SNP2HLA
employs the assayed SNPs, together with a reference panel,
to impute HLA SNPs (if they were not already on the
genotyping array), HLA alleles (HLA-A, HLA-B, HLA-C,
HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, and
HLA-DRB1), and known amino acid polymorphisms
within those HLA genes. These imputed variants can then
be analyzed in the same way as assayed genotypes.
Hence, in addition to using HIBAG, we employed
SNP2HLA v1.0.2 [35] to impute 8,961 HLA SNPs, eight
HLA alleles, and amino acid polymorphisms, based on
the T1DGC reference panel, in the European GWA,
Immunochip, and North American dataset. The non-
SNP imputed markers were coded as present/absent.
Quality control for the combined SNP + imputed marker
data included: (1) removal of imputed SNPs that were
already assayed on the array; (2) within each dataset
(UK2, NL, Finn, IT), removal of SNPs/markers with
MAF <1 %, missingness >10 %, deviation from Hardy-
Weinberg equilibrium (HWE) in controls P <5 × 10−6,
differential case/control missingness P <10−3, and re-
moval of individuals with >10 % missingness; (3) re-
moval of SNPs/markers that were not present in the
four European datasets (UK2, NL, Finn, IT); (4) removal
of SNPs/markers with differential case/control missing-
ness P <10−3 across the combined data; and (5) removal
of SNPs/markers not on the North American imputed
dataset. For the Immunochip data, QC included: (1) re-
moval of imputed SNPs already assayed; (2) SNP/marker
filtering by MAF <0.5 %, missingness >10 %, deviation
from HWE in controls P <10−3, and (3) differential case/
control missingness P <10−3, and removal of individuals
with missingness >10 %. We verified that the imputed
markers included in genomic risk scores had high im-
putation accuracy (r2 > 0.8) in the training data. The final
SNPs + imputed marker European data consisted of
507,321 markers (500,821 assayed SNPs and 6,500 im-
puted markers) over 11,912 individuals (5,552 of which
were DQ2.5+); after removal of individual assayed in the
UK GWA data, the Immunochip dataset had 7,803 indi-
viduals, of which 4,732 were DQ2.5+, with 24,555 SNPs/
markers (approximately 17,800 assayed SNPs and ap-
proximately 6,700 imputed markers) common with the
other datasets. For the DQ2.5-specific GRS (GRS-
DQ2.5), only SNPs present in the North American
dataset were used in cross-validation, so that all SNPs
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in external validation. SNP2HLA had approximately 100 %
concordance with HIBAG’s DQ2.5+ classification.
Validation of the published risk score
We used the previously published GRS14 risk score
(comprising 228 SNPs, available at [44]), which is given
in terms of rs IDs, reference alleles, and a weight, to pro-
duce a per-individual score (using plink –score). The
final score for each individual is the sum of the minor al-
lele dosages of each SNP, weighted by the published
weights. Four SNPs in this score were not found in the
North American post-QC genotype data and were ex-
cluded; these four SNPs had relatively low weight
(ranked 59th or lower, out of 228) and thus their
absence is unlikely to have substantially affected the pre-
dictive power of the final model.
Cross-validation and novel genomic risk scores
We used the tool SparSNP [30], which fits L1/L2-penalized
support-vector machine (SVM) models to SNP data, in
10 × 10-fold cross-validation on the European GWA
dataset. Briefly, these models are additive in the minor
allele dosage {0, 1, 2}, and take into account all SNPs
(or other markers) in the data, however, only a propor-
tion of the SNPs/markers receive a non-zero weight,
tuned by the L1 penalty (higher penalties lead to fewer
SNPs/markers with non-zero weight), together with an
L2 (ridge) penalty in the range of 10−6 to 103. The opti-
mal penalties were determined via cross-validated AUC.
We have previously shown that such penalized models
produce superior predictive ability for CD compared
with several widely-used alternatives [12]. We evaluated
a range of L1/L2-penalized models over a grid of penal-
ties, with the optimal model selected by the best aver-
age AUC. For cross-validation, the reported AUC is a
LOESS-smoothed average over the 10 × 10 = 100 test
sets. For independent validation, we derived a final con-
sensus model consisting of the SNPs selected in >60 %
of the replications, with corresponding weights being
the average weights over the replications (the final risk
scores are given in Additional files 2 and 3). The con-
sensus model was taken and tested without further
modification on the North American dataset. Improve-
ment in case/control discrimination (AUC) was tested
using Harrell’s two-sided test for paired concordance
(rcorrp.cens in R package Hmisc) [45], and 95 % confi-
dence intervals for the AUC were computed using
DeLong’s method (R package pROC) [46].
The ratio of non-CDs incorrectly implicated per CD
correctly implicated
We calculated the ratio r of non-CD individuals incor-
rectly implicated per CD case correctly implicated asr = (1 ‐ PPV)/PPV, where PPV is the positive predict-
ive value, calculated as
PPV ¼ sens prev
sens prevþ 1−specð Þ  1−prevð Þ ;
where sens, spec, and prev are the sensitivity, specificity,
and prevalence (as a proportion of the population under
consideration), respectively, computed for each possible
risk cutoff (forming the ROC curve). This ratio is also
the reciprocal of the post-test odds of disease, that is, 1 /
(likelihood-ratio × pre-test-odds). In estimating the PPV
for the DQ2.5+ subgroup we assumed a prevalence of
10 %, equivalent to the prevalence of individuals with
high background risk of CD, such as family history of
the disease.
To evaluate the difference in the ratios between two
risk scores, we used a stratified bootstrap procedure in
the test data, whereby B = 10,000 replications were
drawn (sampled with replacement), the rank statistics
were estimated within each replicate for each risk score
separately, and the average over the differences in the
ratios was reported as the final bootstrap estimate, with
95 % approximate confidence intervals for the difference
derived using the 0.025 and 0.975 quantiles of the boot-
strapped differences.
Results
Independent validation of genomic risk scores for CD
We applied the previously published GRS14 to the
North American dataset and evaluated its predictive
power using receiver-operating characteristic (ROC)
curves (Fig. 1). The GRS14 model achieved AUC = 0.831
(95 % CI 0.808-0.854), indicating that the majority of the
predictive power of the GRS14 model, previously esti-
mated at AUC = 0.86-0.9 [8] on the Italian, Dutch, and
Finnish datasets, was maintained in the North American
dataset. For comparison, we also trained MultiBLUP [11]
on the same European data and tested it on the North
American dataset with identical results (AUC = 0.831,
95 % CI 0.808-0.85; Additional file 1: Figure S2), and in
addition employed the same L1/L2-regularized SVMs in
cross-validation within the North American data, yield-
ing similar results (maximum average cross-validated
AUC = 0.823, Additional file 1: Figure S3). Further,
there were no substantial differences in the genomic
scores between CD cases diagnoses with different diag-
nosis methods (Additional file 1: Supplementary Results
and Figure S4).
In comparison to the GRS14, the 3-level haplotype risk
method had substantially lower predictive power, with
AUC = 0.773 (95 % CI 0.751-0.795). The GRS model
trained on the European GWA SNPs together with





















HLA haplotype risk (AUC=0.773)
Fig. 1 ROC curves for classifying all CD cases and controls using
different predictors in the North American dataset. GRS14: the
published GRS (trained on the UK2 dataset); GRS-imputed: a GRS
trained on all European GWA datasets (UK, Dutch, Finnish, Italian),
consisting of SNPs and SNP2HLA imputed markers; HLA haplotype
risk: a 3-level risk score based on the HLA haplotype status
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the AUC over GRS14 by +0.007 (AUC = 0.838, CI 0.816-
0.860, P <10−6 value for paired concordance test against
the GRS14) (Fig. 1). However, training a similar GRS-
imputed model on the combined Immunochip + GWA
dataset resulted in reduced performance relative to the
GWA-only model (AUC = 0.835, 0.813-0.858, P <10−6
against the GRS-imputed model trained on the GWA
data only), despite the larger sample size (Additional
file 1: Figure S2).
Celiac disease risk prediction within the HLA-DQ2.5+
subgroup
While risk scores that discriminate CD cases from con-
trols in the general population are useful, a more press-
ing clinical question is whether discrimination is
possible within the HLA-DQ2.5+ subgroup of individ-
uals, who are at the highest risk for CD among all HLA+
individuals. It is estimated that approximately 90 % of
HLA+ individuals are DQ2.5+, with those that are
DQ2.5-homozygous being at greater risk for CD than
those that are DQ2.5-heterozygous [26, 47–49].
Restricting our analysis to DQ2.5+ individuals, we
trained two new GRSs, one using a sparse linear
model of SNPs only (GRS-DQ2.5), and another built
similarly to GRS-DQ2.5 but also utilizing markers
imputed by SNP2HLA (GRS-DQ2.5-imputed). Thesenew GRSs were then compared to three other pre-
dictive models:
1. the imputed DQ2.5 zygosity status for each
individual (DQ2.5-zygosity),
2. the 3-level HLA haplotype risk score (HLA-
haplotype-risk),
3. and the published GRS14.
The GRS-DQ2.5 and GRS-DQ2.5-imputed models
were evaluated using the average AUC over 10 × 10-fold
cross-validation on the DQ2.5+ European GWA sam-
ples. For GRS-DQ2.5, the maximum AUC achieved was
0.727 at 2,513 SNPs with non-zero weight together with
an L2 penalty of 1. For the GRS-DQ2.5-imputed, the
best AUC was 0.74 at 3,317 non-zero weight SNPs/
markers using an L2 penalty of 1 as well (Fig. 2) (for the
results of GRS-DQ2.5 using other L2 penalties see
Additional file 1: Figure S5).
To externally validate these models, we utilized the
North American DQ2.5+ individuals (n = 1,237, 1,094
cases and 143 controls) (Fig. 3a). The highest perform-
ance was observed for GRS-DQ2.5-imputed, achieving
an AUC of 0.73 (95 % CI 0.687-0.772), followed by GRS-
DQ2.5 with AUC = 0.718 (95 % CI 0.676-0.761) and
the GRS14 with AUC = 0.669 (95 % CI 0.625-0.713).
The HLA-haplotype-risk and DQ2.5-zygosity models
achieved AUCs of 0.634 (95 % CI 0.597-0.671) and
0.558 (95 % CI 0.534-0.582), respectively. Training
similar models on a combined Immunochip and
GWA dataset resulted in lower externally validated AUC
of 0.707 (Additional file 1: Supplementary Results).
In a clinical setting, it is desirable to maintain high
sensitivity, that is, capturing most CD cases while incur-
ring a cost of some false positives (reduced specificity).
In considering the corresponding region of the ROC
curve with sensitivity >0.9, while both the haplotype risk
model and the GRS14 model had overall slightly higher
specificity than the zygosity status, the greatest increase
in specificity was observed for the GRS-DQ2.5 and
GRS-DQ2.5-imputed models (specificity of 0.29 and
0.32, respectively, compared with specificity = 0.15 for
the GRS14).
Utility of genomic risk scores in reducing unnecessary
follow-up tests in the HLA-DQ2.5+ subgroup
In a clinical setting, a reduction in the number of un-
necessary tests to screen for a disease or secure a diag-
nosis is desirable. The utility of a GRS for reducing
unnecessary tests can be measured using the ratio of
non-CD incorrectly implicated as CD to those CD cases
correctly implicated (given that neither the proposed
GRS nor HLA typing can act as a sole diagnostic for
CD, we use the term ‘implicate’ as distinct from
Fig. 2 Cross-validation results for the GRS-DQ2.5 and GRS-DQ2.5-imputed models in the European GWA data. 10 × 10 cross-validated AUC
(LOESS-smoothed) for the novel GRS-DQ2.5 model trained on the DQ2.5+ subset of the European GWA data (n = 5,552), as a function of the
number of SNPs assigned a non-zero weight in the model. Maximum AUC was 0.727 achieved at 2,513 SNPs with non-zero weight when considering
only SNPs (GRS-DQ2.5) and AUC of 0.74 at 3,317 SNPs/markers when using SNPs and SNP2HLA-imputed markers (GRS-DQ2.5-imputed)
Fig. 3 External validation results on the DQ2.5+ individuals in the North American dataset. a ROC curves for case/control prediction and b non-CD
implicated per CD correctly implicated, ((1 – PPV)/PPV, equivalent to 1/(post-test-odds of disease)) versus sensitivity, for models developed on the
European data and tested on the DQ2.5+ subset of the North American cohort. The DQ2.5 zygosity is the number of DQ2.5 alleles for each individual
(heterozygous = 1, homozygous = 2). We assumed a CD prevalence of 10 % in the DQ2.5+, corresponding to a baseline implication ratio of 9:1, that is,
all DQ2.5+ implicated as having CD at 100 % sensitivity
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tive to the sensitivity, as one should seek to minimize
the former while maximizing the latter. A lower ratio
(ideally <1) at high sensitivity indicates a better ability to
avoid falsely implicating non-CD individuals as being at
high CD risk, while capturing a substantial number of
CD cases. Unlike the sensitivity and specificity, this ratio
depends on the true prevalence of CD in the population
being tested (here, all DQ2.5+ individuals). People at
high risk of CD, for instance, due to a family history of
the illness, have a 10 % prevalence of disease [50].
Therefore for this modeling we likewise assumed a
prevalence of 10 %, leading to a baseline ratio of 9:1
(equivalent to all DQ2.5-positive individuals being rec-
ommended for follow-up testing).
Overall, both the GRS-DQ2.5 and GRS-DQ2.5-imputed
models implicated fewer non-CD individuals per CD case
correctly implicated than the GRS14, the DQ2.5-zygosity,
or the HLA-haplotype-risk score (Fig. 3b). Note that since
DQ2.5-zygosity within the DQ2.5+ individuals is limited
to heterozygous (one risk allele) and homozygous (two
risk alleles), the main point of interest for the curve is
the one indicating heterozygotes, leading to approxi-
mately 3.5:1 incorrect implications but achieving only
20 % sensitivity. By comparison, both GRS-DQ2.5 and
GRS-DQ2.5-imputed models achieved a ratio of ap-
proximately 2:1 at the same sensitivity as DQ2.5-zygosity.
Similarly, the main point of interest for HLA-haplotype-
risk separates high from medium risk, with a sensitivity of
50 % and approximately 4:1 incorrect implications, a level
improved upon by GRS14, GRS-DQ2.5, and GRS-DQ2.5-
imputed.
If we analyze the performance of the GRS at a sensitiv-
ity of 90 % (comparable to that achieved by CD ser-
ology), the incorrect implications ratio was lowest for
GRS-DQ2.5-imputed (6.7:1), followed by GRS-DQ2.5
(6.9:1) and GRS14 (8.5:1). To evaluate the stability of
these results we performed stratified bootstrap analysis
of the North American samples (B = 10,000 replications).
The greatest improvements in the average bootstrap
reduction in incorrect implications ratio was from GRS-
DQ2.5-imputed at a reduction of 2.17 (95 % CI 1.35-
3.02) over the 9:1 baseline, followed by GRS-DQ2.5 and
GRS14, at 1.96 (1.16-2.78) and 1.61 (0.55-2.64), respect-
ively (see Additional file 1: Figure S7 for results limited
to sensitivity ≥90 %).
Discussion
More widespread use of genomic risk prediction in auto-
immune disease has been hampered by the inability to
identify compelling advantages over existing approaches,
mainly HLA haplotyping. Here, we have focused our
analysis on individuals carrying the HLA-DQ2.5 hetero-
dimer, which is the most common risk heterodimer andalso imparts the highest risk for CD. Existing diagnostic
tests are not useful in the absence of active disease and
cannot predict risk of future disease. While approaches
based on HLA haplotypes, including DQ2.5 zygosity and
a HLA haplotype risk score [33], provide some predict-
ive power, we have demonstrated that genomic risk
scores focused on DQ2.5+ individuals have substantially
higher predictive power than either approach, extending
our previous findings [8]. For the DQ2.5+ subset of
individuals in particular, our results highlight that
while particular HLA alleles are a necessary condi-
tion for CD, they are far from a sufficient condition,
and that genomic analysis can better uncover further
sources of risk not adequately captured by DQ2.5 zy-
gosity alone.
Our genomic risk scores were based on direct model-
ing of SNPs, both within and outside of HLA. Further,
combining the genome-wide SNP data with imputed
HLA markers, including HLA alleles outside the well-
known HLA-DQA1 and HLA-DQB1 genes, imputed
HLA SNPs, and HLA amino acid substitutions [35], led
to an increase in predictive power on the North American
dataset, thus suggesting that tools for imputing non-
traditional risk factors have an important role in future
predictive modeling.
The increased precision of both GRS-DQ2.5 and GRS-
DQ2.5-imputed translated to an average increased saving
of approximately two unnecessary follow-ups per justi-
fied follow-up (a 22-24 % average reduction), compared
with the alternative strategy of considering all DQ2.5+
individuals for follow-up testing. Importantly, at this
level, GRS-DQ2.5 and GRS-DQ2.5-imputed still cap-
tured 90 % of DQ2.5+ CD cases. These results suggest
that a GRS specific to HLA-DQ2.5+ individuals can
achieve substantial cost savings while incurring only
a small loss in sensitivity, relative to implicating all
DQ2.5+ individuals for more intensive screening and
follow-up. In real-life clinical practice, measures could be
put in place to overcome the slight loss of sensitivity or
any negative consequences. For instance, combining the
GRS with CD serology would enable the high sensitivity
of the latter test to minimize the chance of true CD cases
being overlooked but still leverage the discriminatory
power of the GRS. Patients would still be advised to seek
medical review if they developed symptoms suggestive of
CD. Further, the top 15-20 % of CD cases in terms of
GRS-DQ2.5 were estimated to be detectable at a level of
1 unnecessary follow-up per true CD case, suggesting
that relatively high confidence of CD can be conferred
upon individuals with the highest GRS-DQ2.5/GRS-
DQ2.5-imputed scores, thus potentially only requiring
CD serology for the subset of individuals with moderate
risk, who cannot be confidently predicted by the GRS to
have CD or be healthy.
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of genomic risk scores for CD remain to be determined in
prospective clinical studies where genomic profiles are
undertaken from the outset. If prospective studies can
establish the clinical value of the GRS and link it to CD
risk, we envisage that clinicians ordering this test will
be provided with a weighted GRS value that links to a
scale of CD risk. They would then use this score to
complement clinical risk stratification and guide the
most suitable advice on long-term follow-up and/or
further investigations.
Several potential roles for the GRS can be pro-
posed. First, guiding ongoing care in people at-risk of
CD who are also HLA-DQ2.5+. Several recent large
prospective studies have reinforced the importance of
HLA-DQ2.5 for CD development in childhood, with
environmental factors such as age of gluten introduc-
tion or breastfeeding having little, if any, impact on
the proportion of children who ultimately develop
CD [25, 26, 51]. These findings have prompted some
experts to recommend increased surveillance for CD
in children with a positive family history of CD who
are HLA-DQ2.5, especially if DQ2.5 homozygous.
The increased predictive power of our GRS-DQ2.5
beyond the information afforded by DQ2.5 zygosity
status alone is likely to provide greater clinical utility
for predicting risk in this important subgroup of
individuals.
Second, genomic data may also be able to inform
CD prognosis, such as the likelihood of complicated
(refractory) disease or the natural history of latent
CD (positive CD-serology and HLA susceptibility but
a normal small bowel), or other aspects of care such as
response to the gluten-free diet. Finally, another ap-
proach may be to combine a GRS with serology to
optimize risk stratification for CD and determine who
will benefit most from definitive small bowel biopsy.
Such a strategy could leverage the strengths of each test:
the high sensitivity for active CD using CD serology and
the fine-grained CD risk quantification of the GRS,
including its ability to provide predictive information
and exclude CD. A major benefit of genetic testing in
the diagnostic work-up of CD is that, unlike serology
and small bowel histology, accurate results are not
dependent on active gluten intake. This is particularly
relevant, as the gluten-free diet has been adopted by
10 % or more of the population in many Western
countries, rendering traditional tests inaccurate. Es-
tablishing the clinical utility of genomic testing in CD
will also support the feasibility of a genomics-based
platform for a range of other autoimmune diseases,
where both HLA and non-HLA genetic contributions
are important as well, and which commonly overlap
with CD [14].Conclusions
Our findings highlight the value of genomic risk scores
that target a clinically relevant subgroup of individuals
at risk for CD. Genomic risk scores that utilize genome-
wide SNPs, HLA alleles, and amino acid substitutions
provided the highest predictive power in individuals who
are DQ2.5+, surpassing that of approaches based on
small numbers of well-known risk haplotypes or models
of SNPs only. This improved predictive power dir-
ectly translates to an ability to better stratify DQ2.5+
individuals by CD risk, meaning that for each justi-
fied test, two follow-up tests in people unlikely to
develop CD could be avoided, which improves both
patient care and healthcare delivery. Future clinical
studies will enable optimization of such risk scores
to particular clinical settings and assess how to best
integrate genomic risk prediction with the current
clinical diagnostic pathways for CD. Our results in
CD suggest that employing such genomic-based ap-
proaches in other autoimmune disease is both feas-
ible and potentially of clinical utility.Additional files
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